Letrozole Bluefish

Letrozole, the active ingredient in Letrozole Bluefish, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the management of hormone receptor‑positive breast cancer in postmenopausal women, where it reduces estrogen production that can stimulate tumor growth.

GNH USA supplies Letrozole Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics to meet global procurement standards and timely delivery.

Letrozole is an aromatase inhibitor used in the treatment of hormone‑dependent breast cancer.

- Metastatic hormone receptor‑positive breast cancer in postmenopausal women: slows tumor progression and improves survival. - Adjuvant therapy for early‑stage hormone receptor‑positive breast cancer: reduces risk of disease recurrence after surgery. - Neoadjuvant treatment before surgery in postmenopausal breast cancer: may shrink tumor size to facilitate breast‑conserving procedures.

Letrozole may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild gastrointestinal upset. - Headache: mild to moderate.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases or hepatitis. - Bone fracture: increased risk of osteoporosis‑related fractures. - Pulmonary embolism: blood clot in lung vessels. - Myocardial infarction: heart attack. - Anaphylaxis: severe allergic reaction.

When prescribing Letrozole, clinicians should consider several safety measures.

- Monitor bone health: assess bone mineral density and consider calcium/vitamin D supplementation. - Evaluate liver function: check hepatic enzymes before initiation and periodically during therapy. - Assess cardiovascular risk: review history of thromboembolic events or myocardial disease. - Contraindicated in pregnancy: teratogenic, category X; ensure effective contraception. - Avoid use in premenopausal women unless ovarian suppression is confirmed. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Letrozole interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Tamoxifen: antagonistic effect reduces overall estrogen suppression. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower letrozole plasma concentrations. - Strong CYP2A6 inhibitors (e.g., fluvoxamine): may increase letrozole exposure and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin: potential increase in INR and bleeding risk. - CYP2C19 substrates (e.g., omeprazole): possible altered metabolism requiring monitoring. - Statins (HMG‑CoA reductase inhibitors): monitor for myopathy when combined with letrozole.